Product Information
BUDESONIDE 2 MG RECTAL FOAM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $9.5641 per GM under NDC 45802062786. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Apr 12, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802062786
Classification
Generic
Dosage Form
AEROSOL, FOAM
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
BUDESONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215328FDA Approved
4/12/2023
TE Code
AB
On Market Since
4/17/2023
Pharmacological Classes
Price Statistics
The NADAC for BUDESONIDE 2 MG RECTAL FOAM has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 15.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.5641 per GM |
|---|---|
| All-time high | $9.5641 (Sep 30, 2026) |
| All-time low | $7.0795 (Aug 21, 2024) |
| 52-week high | $9.5641 |
| 52-week low | $9.3010 |
| Median price | $9.2909 |
| Average price | $8.8587 |
| Largest weekly change | +6.7% (Oct 23, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
budesonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUDESONIDE 2 MG RECTAL FOAM?
The current National Average Drug Acquisition Cost (NADAC) for BUDESONIDE 2 MG RECTAL FOAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $9.5641 per GM (NDC 45802062786), effective Sep 30, 2026.
How has the price of BUDESONIDE 2 MG RECTAL FOAM changed over time?
Over the history we have for it, the NADAC for BUDESONIDE 2 MG RECTAL FOAM has risen 15.8%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for BUDESONIDE 2 MG RECTAL FOAM?
Since Apr 17, 2024, the NADAC for BUDESONIDE 2 MG RECTAL FOAM has ranged from a low of $7.0795 (Aug 21, 2024) to a high of $9.5641 (Sep 30, 2026), with a median of $9.2909 per GM.
Are there cheaper alternatives to BUDESONIDE 2 MG RECTAL FOAM?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUDESONIDE 2 MG RECTAL FOAM, is $9.4092 per GM — about 2% below BUDESONIDE 2 MG RECTAL FOAM.
Who manufactures BUDESONIDE 2 MG RECTAL FOAM?
BUDESONIDE 2 MG RECTAL FOAM (NDC 45802062786) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.